Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative HAI Chemotherapy for HCC with PVTT
NCT01834963Phase 2Unknown
- Sponsor
- Kansai Hepatobiliary Oncology Group
- Start
- Mar 2013
- Primary completion
- Feb 2018
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa, Cisplatin micelle injection (HA132) and fluorouracil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Kansai Hepatobiliary Oncology Group. Primary endpoint: Two-year overall survival rate at 2 years. Status: unknown.
02
Drugs
interferon alfaCisplatin micelle injection (HA132)fluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01834963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834963.